平行会议三：抗体与医学 （分会主席：朱祯平、华绍炳)
随着市场上大批“重磅炸弹”式抗体药物取得的高成功率，单克隆抗体近年来已经成为一类用来治疗诸如癌症、感染性疾病和炎症性疾病的新型药物。这种现象很大程度上取决于抗体人源化技术和全人源抗体技术的发展。本分会的演讲内容将包括有关抗体技术最新的发展动向、临床应用、抗体生产、诊断应用以及知识产权等话题。
Zhenping Zhu, MD, Ph.D.
Vice President and Global Head, Protein Sciences and Design, Novartis Biologics
Talk title: Researching and developing next generation of antibody-based therapeutics
S. Benjamin Hua, Ph.D.
Adjunct Professor, ZCNI; President & CEO, Avalon BioSciences
Yajun Guo, Ph.D.
Director, SMMU Cancer Institute, Shanghai; President, Chinese Antibody Engineering Center
Talk title: New version of humanized antibody for anti-cancer therapy
Peter Luo, Ph.D.
Director, Vaccine and Biologics Research, Merck & Co., Inc.
Talk title: Development of therapeutic antibodies using adaptor-directed display of designer antibody libraries
Maurice Zaudeer, Ph.D.
President and CEO, Vaccinex, Inc.
Talk title: Therapeutic antibodies selected from immunoglobulin gene libraries expressed in mammalian cells
Cheng-I Wang, Ph.D.
Principle Investigator, Biomedical Sciences, Singapore
Talk title: Therapeutic antibody against emerging infectious diseases
Larry Witte, Ph.D.
Vice President, ImClone Systems, Eli Lilly
Talk title: Targeting cancer with therapeutic antibodies
Jaumes Pons, Ph.D.
Vice President & CSO, Rinat Pharmaceuticals, Pfizer
Talk title: Tanezumab: NGF antibodies as a new mechanism for pain control
Li Yan, Ph.D.
Director, Clinical Oncology, Merck & Co., Inc.
Talk title: Clinical Development of Antibody Therapeutics in Oncology
Cline Wood, Ph.D.
CSO, Bayer Schering
Talk title: Building a biologics pipeline with antibodies, coagulation factors and HTP optimization
Joe Zhou, Ph.D.
Visiting Professor, Peking University; CEO, Genor BioPharma, Wison Group
Talk title: Biopharmaceutical: the way forward
James Zhu, JD, Ph.D., MBA
Partner, Perkins Coie, LLC
Talk title: The complexity of IP issues surrounding therapeutic antibodies and technologies thereof
Guoliang Yu, Ph.D.
President and CEO, Epitomics, Inc.
Talk title: Better antibodies, better science, better life: applications of RabMabs
